Literature DB >> 34791720

Myocardial blood flow is the dominant factor influencing cardiac magnetic resonance adenosine stress T2.

Jill J Weyers1, Venkat Ramanan1, Ahsan Javed2, Jennifer Barry1, Melissa Larsen1, Krishna Nayak2, Graham A Wright1,3,4, Nilesh R Ghugre1,3,4.   

Abstract

Stress imaging identifies ischemic myocardium by comparing hemodynamics during rest and hyperemic stress. Hyperemia affects multiple hemodynamic parameters in myocardium, including myocardial blood flow (MBF), myocardial blood volume (MBV), and venous blood oxygen levels (PvO2 ). Cardiac T2 is sensitive to these changes and therefore is a promising non-contrast option for stress imaging; however, the impact of individual hemodynamic factors on T2 is poorly understood, making the connection from altered T2 to changes within the tissue difficult. To better understand this interplay, we performed T2 mapping and measured various hemodynamic factors independently in healthy pigs at multiple levels of hyperemic stress, induced by different doses of adenosine (0.14-0.56 mg/kg/min). T1 mapping quantified changes in MBV. MBF was assessed with microspheres, and oxygen consumption was determined by the rate pressure product (RPP). Simulations were also run to better characterize individual contributions to T2. Myocardial T2, MBF, oxygen consumption, and MBV all changed to varying extents between each level of adenosine stress (T2 = 37.6-41.8 ms; MBF = 0.48-1.32 mL/min/g; RPP = 6507-4001 bmp*mmHg; maximum percent change in MBV = 1.31%). Multivariable analyses revealed MBF as the dominant influence on T2 during hyperemia (significant β-values >7). Myocardial oxygen consumption had almost no effect on T2 (β-values <0.002); since PvO2 is influenced by both oxygen consumption and MBF, PvO2 changes detected by T2 during adenosine stress can be attributed to MBF. Simulations varying PvO2 and MBV confirmed that PvO2 had the strongest influence on T2, but MBV became important at high PvO2 . Together, these data suggest a model where, during adenosine stress, myocardial T2 responds predominantly to changes in MBF, but at high hyperemia MBV is also influential. Thus, changes in adenosine stress T2 can now be interpreted in terms of the physiological changes that led to it, enabling T2 mapping to become a viable non-contrast option to detect ischemic myocardial tissue.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adenosine stress; cardiac MRI T2 mapping; heart disease; myocardial blood flow; myocardial blood volume; stress imaging

Mesh:

Substances:

Year:  2021        PMID: 34791720      PMCID: PMC8828684          DOI: 10.1002/nbm.4643

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  82 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Myocardial BOLD imaging at 3 T using quantitative T2: application in a myocardial infarct model.

Authors:  Nilesh R Ghugre; Venkat Ramanan; Mihaela Pop; Yuesong Yang; Jennifer Barry; Beiping Qiang; Kim A Connelly; Alexander J Dick; Graham A Wright
Journal:  Magn Reson Med       Date:  2011-05-31       Impact factor: 4.668

3.  Relation between myocardial oxygen consumption and myocardial blood volume: a study using myocardial contrast echocardiography.

Authors:  D Elizabeth Le; Jian-Ping Bin; Matthew P Coggins; Kevin Wei; Jonathan R Lindner; Sanjiv Kaul
Journal:  J Am Soc Echocardiogr       Date:  2002-09       Impact factor: 5.251

4.  High dose adenosine stress echocardiography for noninvasive detection of coronary artery disease.

Authors:  A D Djordjevic-Dikic; M C Ostojic; B D Beleslin; J Stepanovic; Z Petrasinovic; R Babic; S M Stojkovic; G Stankovic; M Nedeljkovic; I Nedeljkovic; V Kanjuh
Journal:  J Am Coll Cardiol       Date:  1996-12       Impact factor: 24.094

5.  Adenosine-stress dynamic myocardial CT perfusion imaging: initial clinical experience.

Authors:  Gorka Bastarrika; Luis Ramos-Duran; Michael A Rosenblum; Doo Kyoung Kang; Garrett W Rowe; U Joseph Schoepf
Journal:  Invest Radiol       Date:  2010-06       Impact factor: 6.016

6.  Native T1 mapping for characterization of acute and chronic myocardial infarction in swine: Comparison with contrast-enhanced MRI.

Authors:  Xi Liu; Jiang-Long Hou; Zhi-Gang Yang; Chun-Chao Xia; Lin-Jun Xie; Peng-Fei Ye; Wan-Lin Peng; Lei Li; Meng-Xi Yang; Ying-Kun Guo
Journal:  J Magn Reson Imaging       Date:  2017-10-16       Impact factor: 4.813

7.  Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance.

Authors:  Theodoros D Karamitsos; Ntobeko A B Ntusi; Jane M Francis; Cameron J Holloway; Saul G Myerson; Stefan Neubauer
Journal:  J Cardiovasc Magn Reson       Date:  2010-11-16       Impact factor: 5.364

Review 8.  The future of pharmacologic stress: selective A2A adenosine receptor agonists.

Authors:  Manuel D Cerqueira
Journal:  Am J Cardiol       Date:  2004-07-22       Impact factor: 2.778

9.  Regional myocardial blood volume and flow: first-pass MR imaging with polylysine-Gd-DTPA.

Authors:  N Wilke; K Kroll; H Merkle; Y Wang; Y Ishibashi; Y Xu; J Zhang; M Jerosch-Herold; A Mühler; A E Stillman
Journal:  J Magn Reson Imaging       Date:  1995 Mar-Apr       Impact factor: 4.813

10.  Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance.

Authors:  Vanessa M Ferreira; Stefan K Piechnik; Erica Dall'Armellina; Theodoros D Karamitsos; Jane M Francis; Robin P Choudhury; Matthias G Friedrich; Matthew D Robson; Stefan Neubauer
Journal:  J Cardiovasc Magn Reson       Date:  2012-06-21       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.